SEA-CD40 Combination Therapy for Non-Small Cell Lung Cancer

Recruiting in Palo Alto (17 mi)

+33 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Seagen Inc.

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called SEA-CD40 to see if it can help treat certain types of cancer when used with other medications. It targets patients with hard-to-treat melanoma and advanced lung cancer. The drug works by boosting the immune system and working with other drugs to attack cancer cells. This new treatment option has the potential to generate anticancer immunity through various mechanisms.

Research Team

Jonathan Hayman, MD

Principal Investigator

Seagen Inc.

Eligibility Criteria

This trial is for adults with certain types of cancer, like melanoma that's returned or can't be surgically removed, and NSCLC that has spread. They must not have had CD40-targeted therapy before, no other cancers in the last 3 years, no autoimmune diseases treated in the past 2 years, and they shouldn't be on high doses of steroids or have active brain metastases.

Inclusion Criteria

My cancer is confirmed by lab tests and cannot be removed by surgery.

Participants must meet specific criteria for each cohort as outlined in the text

Exclusion Criteria

My cancer has spread to my brain or the protective layers of my brain.

I have had another type of cancer in the last 3 years.

I have been treated with CD40-targeted therapy before.

See 3 more

Treatment Details

Interventions

Carboplatin (Alkylating agents)
Pembrolizumab (Monoclonal Antibodies)
Pemetrexed (Anti-metabolites)
SEA-CD40 (Monoclonal Antibodies)

Trial OverviewThe study tests an experimental drug called SEA-CD40 combined with pembrolizumab for melanoma patients; and SEA-CD40 with pembrolizumab, carboplatin, and pemetrexed for those with advanced NSCLC. It aims to see if these combinations are effective against these cancers.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: NSCLC ArmExperimental Treatment4 Interventions

SEA-CD40 + pembrolizumab + pemetrexed + carboplatin

Group II: Melanoma ArmExperimental Treatment2 Interventions

SEA-CD40 + pembrolizumab

Carboplatin is already approved in Canada for the following indications: